OVX836 clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses OVX836 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Osivax (6)
Often tested with
Tested in the same studies.
Influenza Vaccines (2) · Intramuscular Route of Administration (1)
Studies
Open first, then newest update. How each study uses OVX836 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μgCompletedPhase 2OsivaxNCT05569239Written as OVX836 480µg
- Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836CompletedPhase 2OsivaxNCT06582277Written as OVX836 shot
- Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.CompletedPhase 2OsivaxNCT05284799Written as OVX836 480µg
- Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.CompletedPhase 2OsivaxNCT05734040Written as OVX836 480µg
- Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy SubjectsCompletedPhase 1OsivaxNCT03594890Written as OVX836 (Intranasal)
- Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 YearsCompletedPhase 2OsivaxNCT04192500Written as OVX836